Benitec Biopharma (BNTC) Accumulated Depreciation (2025)

Benitec Biopharma's (BNTC) quarterly Accumulated Depreciation came in at $1.5 million in Q4 2025, up 1.84% quarter-over-quarter from $1.5 million in Q2 2025.

Benitec Biopharma (BNTC) Accumulated Depreciation (2025) Analysis & Trends

Benitec Biopharma has disclosed Accumulated Depreciation across 1 years of filings, most recently posting $1.5 million for Q4 2025.

  • Accumulated Depreciation for Q4 2025 came in at $1.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $1.5 million (changed N/A YoY), and the FY2025 annual result was $1.5 million, changed N/A from the prior year.
  • Accumulated Depreciation came in at $1.5 million for Q4 2025 at Benitec Biopharma, up from $1.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $1.5 million in Q4 2025 to a low of $1.5 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 788,338.31 Bn 788,338.28 Bn -
2 Belite Bio 56,560.00 Bn 56,560.00 Bn -
3 Quantum Biopharma 17,329.30 Bn 17,329.30 Bn -
4 Legend Biotech 3,341.00 Bn 3,340.71 Bn 242.10 Mn
5 Akari Therapeutics 1,727.91 Bn 1,727.91 Bn -
6 Evaxion A 1,536.68 Bn 1,536.67 Bn -
7 Psyence Biomedical 238.34 Bn 238.33 Bn -
8 Vertex Pharmaceuticals 113.42 Bn 106.17 Bn 2.59 Bn
9 Abivax 95.45 Bn 95.45 Bn -
10 Benitec Biopharma 488.21 Mn 488.21 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 1.50 Mn
Jun 30, 2025 1.47 Mn